High-dose chemotherapy with autologous peripheral blood SCT is a common treatment option in several hematological and non-hematological malignancies. So far, prediction of successful stem cell mobilization and harvest is limited. Just recently, hypercholesterolemia was shown to increase mobilization of hematopoietic progenitor cells into the peripheral circulation in mice. On the basis of these results, we performed a retrospective multivariate analysis incorporating a variety of clinical parameters in 83 patients following high-dose cyclophosphamide þ G-CSF treatment. Interestingly, we found a significant positive correlation between stem cell mobilization and harvest for plasma cholesterol and lactate dehydrogenase (LDH) only. Patients with hypercholesterolemia showed a substantially higher median peripheral blood CD34 þ -peak (126 vs 47/lL, P ¼ 0.003), higher median number of harvested CD34
Introduction
Hematopoietic stem cells (HSCs) reside in specific niches in the BM and various signals regulate survival, self-renewal, proliferation, differentiation and trafficking. [1] [2] [3] [4] [5] [6] [7] [8] Egress of HSCs into the peripheral blood (PB) is enhanced by multiple agonists, although the exact mechanisms that regulate this critical process are largely unknown. After treatment with cyclophosphamide and G-CSF, long-term HSC in the BM enter the cell cycle. Additionally, G-CSF induces a reduction of the chemokine stromal cell derived factor 1 (SDF-1) and an increase of its receptor CXCR4 in the BM leading to mobilization of HSCs to the PB. 9 However, only a few factors affecting stem cell mobilization and harvest are known so far. [10] [11] [12] Very recently, Gomes et al. 13 identified hypercholesterolemia to promote stem cell mobilization in mice by also disrupting the SDF-1/CXCR4 axis.
Because hypercholesterolemia is a common phenomenon in patients undergoing stem cell mobilization, we retrospectively examined the role of cholesterol and a number of possible confounding factors on mobilization results and stem cell harvests in a patient cohort undergoing a standard mobilization procedure
Patients and methods

Stem cell mobilization and CD34
þ -measurement We retrospectively identified 104 patients receiving highdose cyclophosphamide for stem cell mobilization between 1997 and 2009 using a clinical database. All were treated with 4000 mg/m 2 cyclophosphamide on day 1 followed by approximately 10 mg/kg lenograstim s.c. from day 8 until the end of stem cell harvest. CD34 þ counts in the PB were analyzed at 2 h after administration of lenograstim. Patients usually proceded to stem cell apheresis, if the peripheral CD34
þ -count exceeded 15/mL. CD34 þ -cells in PB and stem cell harvests were counted using a flow-cytometric (Beckmann Coulter XL or FC 500 flow cytometer; Beckman Coulter, Brea, CA, USA) based two platform protocol. Antibodies used were: CD34-PE, CD45-FITC (Becton Dickinson, Franklin Lakes, NJ, USA). Viability was determined via 7-AAD staining or colony forming unit assay between 1997 and 2004. PB counts were determined using a Micros 600 haematology analyzer (Horiba ABX inc., Irvine, CA, USA). Only CD34 þ -counts from the first stem cell harvest attempt using this mobilization procedure were used from each patient.
Laboratory results and medication
Laboratory results were investigated on the day of starting mobilization procedure or, if not available, up to 14 days prior using an electronic clinical database. Long-term medication was assessed using the patient files.
Statistical analysis
The data were described by median and interquartile range.
Values of CD34
þ cells according to cholesterol levels and other patient characteristics have been compared using non-parametric methods (Wilcoxon test and Spearman's rank correlation where appropriate). Additionally, we fitted an analysis of covariance model to model the influence of patient characteristics, laboratory results on the day of high-dose cyclophosphamide and long-term medication with selected drug classes on the peak CD34 þ cell counts in our data.
All statistical analyses were performed using the SAS software package version 9.1.3 (SAS Institute Inc., Cary, NC, USA) under Windows XP. Significance level was set to 0.05.
Results and Discussion
Out of the 104 patients, 21 did not have cholesterol levels available. With respect to patients' characteristics and lab results, these patients did not deviate systematically from the population finally analyzed. Among the remaining 83 patients included, 33 (39.8%) were identified as having hypercholesterolemia (defined as 46.2 mmol/L). Underlying diagnoses were multiple myeloma (n ¼ 47; 56.6%), non-Hodgkin's lymphoma (n ¼ 29, 34.9%), germ-cell tumors (n ¼ 4, 4.8%), ALL (n ¼ 1, 1.2%), Hodgkin's disease (n ¼ 1, 1.2%), and nasopharyngeal carcinoma (n ¼ 1, 1.2%). The mean number of prior lines of anti-neoplastic therapy was 1.52 (median 1, range 1-6). Statistical analysis revealed no significant difference of laboratory results, patient's characteristics and long-term medication between the groups of normal and elevated cholesterol besides higher triglycerides in the group with higher cholesterol.
We examined the role of cholesterol and a number of additional possible confounding factors shown in Table 1 . Using univariate analyses, a lower number of prior therapy lines (Po0.001), higher lactate dehydrogenase levels (LDH, P ¼ 0.005), lower creatinine (P ¼ 0.025) and higher cholesterol (Po0.001), as well as long-term medication with betablockers (P ¼ 0.039) were significantly correlated with better CD34 þ cell mobilization. However, as expected, cholesterol and TG were highly correlated (Po0.001), TG were excluded from further multivariate analysis as a single factor. A multivariate ANCOVA model then allowed the adjusted assessment of the influencing factors on the peak CD34 þ cell counts and revealed a positive linear dependence on LDH (slope: 0.41, P ¼ 0.047) and on cholesterol (slope: 0.60, P ¼ 0.012) only as shown in Table 1 .
Egan et al. 14 described a very strong correlation of elevated pre-apheresis LDH-levels with better stem cell mobilization and apheresis yields. However, LDH elevation in this study could mainly be attributed to the procedure, that is, G-CSF application itself and as such, more reflected the sensitivity of the BM to G-CSF stimulation. In this study however, we found elevated LDH levels already to be predictive for favorable stem cell mobilization even before the start of the procedure, indicating that LDH may indeed represent a procedure-independent predictive biomarker for HSC mobilization.
Finally, in our cohort, the most predominant predictive biomarker for stem cell mobilization turned out to be plasma cholesterol (Figure 1a ). Using the upper normal limit of 6.2 mmol/L, patients with hypercholesterolemia had a higher median CD34 þ cell peak compared with patients with normal cholesterol levels (126 (interquartile range: 47-174)/mL vs 47/mL (6-98), P ¼ 0.003). The median CD34 þ cell counts in the PB on days 6-17 after standard mobilization are depicted in Figure 1b and showed significantly higher levels on day 12 (88.5 (43-145) vs 14 (3-71)/mL, P ¼ 0.005) and on day 13 (91 (26-174)/mL vs 20 (2.5-65)/mL, P ¼ 0.002). This clinical data is in high accordance with the publication by Gomes et al. 13 in the mouse that could show a major effect of a high-cholesterol diet on the number of circulating progenitor cells. They demonstrated that hypercholesterolemia induced SDF-1 secretion resulting in elevated SDF-1 plasma levels inducing CXCR4
þ -progrenitor cells exit into the PB. 13 In addition, our patient cohort received chemotherapy with cyclophosphamide in combination with G-CSF, which is known to manipulate the SDF-1/CXCR4-interaction as well. 9 Accordingly, the median overall number of , P ¼ 0.024, adjusted to body weight: 9.6 (7.1-15.0) vs 7.4 (5.4-9.1) Â 10 6 /kg, Po0.001) and a sufficient number for at least one SCT (more than 2.0 CD34 þ cells Â 10 6 /kg) was achieved in a remarkably higher proportion (84.9 vs 52.9%, P ¼ 0.004). The comparably high overall yields per patient have been achieved owing to a high number of apheresis procedures (median 5 (interquartile range 4-6)) per patient. In contrast, we found a relatively high failure of the first mobilization attempt in 33.7% of our patients. But, in an unselected cohort of 976 patients, Gertz et al. 12 very recently reported a comparable failure rate of 29.7%. In our patients, during each apheresis median 114.2 (70.1-196.5) Â 10 6 CD34 þ -cells (adjusted to body weight: 1.55 (0.9-2.45) Â 10 6 /kg) have been collected. As expected, we found a very strong correlation between peripheral blood CD34 þ cell counts and apheresis yields on each day (Po0.0001).
In our patient cohort it was not documented whether blood sampling was performed in a fasting or non-fasting state. However, recent investigations indicate only minimal changes in lipid profiles in response to normal food intake. 15 Interestingly, we also found the statistically significant correlation between CD34 þ cell mobilization and cholesterol if median cholesterol levels of all available values of each patient (instead of only pre-mobilization values) were used (data not shown). In addition, the effect of cholesterol was also independent of co-medication with statins. In summary, very recent experimental data suggested a significant influence of cholesterol levels on peripheral progenitor cell mobilization in mice. Our retrospective multivariate analysis including multiple possible factors extends this significant and potentially clinically relevant observation to the human system, as patients with hypercholesterolemia showed better mobilization, higher stem cell yields and a sufficient harvest for at least one autologous transplantation in a remarkably higher proportion. Whether in patients with successfully treated hypercholesterolemia, cholesterol-lowering therapy should be stopped during mobilization therapy in order to increase stem cell harvest will need to be assessed in the context of a clinical trial following prospective validation of the results reported here. Furthermore, it remains to be seen whether this effect is still preserved under stem cell mobilization with other regimens such as plerixafor. þ mononuclear cells in the peripheral blood after mobilization with cyclophosphamide and G-CSF in patients with normal (gray bars) and elevated cholesterol levels (black bars).
